Disease Modifying Therapies For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
{{Infobox
|title=Disease-Modifying Therapies for Alzheimer's Disease
|category=Treatment
|target=Alzheimer's Disease
|status=Approved/Investigational
|phase=Phase I-III
}}
- Mechanism: Humanized IgG1 that binds soluble Aβ protofibrils
- Approval: FDA full approval January 2023
- CLARITY-AD Trial: 27% slowing of cognitive decline at 18 months
- Dose: 10 mg/kg IV every 2 weeks
- ARIA risk: ~12.6% (ARIA-E), 17.3% (ARIA-H)
- Amyloid removal: Significant plaque reduction at 18 months
- Mechanism: N-terminal pyroglutamate Aβ specific antibody
- Approval: FDA approval July 2024
- TRAILBLAZER-ALZ 2: 35% slowing of decline in low/medium tau population
- Dose: 350 mg IV every 4 weeks after titration
- Limited dosing: Can stop at amyloid clearance
- ARIA risk: 24% (any ARIA)
- Mechanism: Human IgG1 against Aβ aggregates
- Approval: Accelerated approval 2021 (controversial)
- ENGAGE/EMERGE trials: Mixed results, high dose showed benefit
- Discontinued: Manufacturer discontinued 2024
- ARIA risk: 35% (ARIA-E)
- Mechanism: Anti-Aβ protofibril antibody
- Phase III: CREAD trials (negative)
- API-AD trial: Ongoing in autosomal dominant AD
- Mechanism: Fully human IgG1
- Phase III: Graduate trials (negative)
- GRADUATE 1/2: Did not meet primary endpoint
- Mechanism: Anti-soluble Aβ mid-domain
- Phase III: EXPEDITION trials (negative)
- DIAN-TU: Ongoing in preclinical AD
- Mechanism: BACE1/2 inhibitor
- Phase III: Stopped for cognitive worsening
- EPOCH: Negative in mild-to-moderate AD
- Mechanism: BACE inhibitor
- Phase III: Stopped for liver toxicity
- AMARANTH/DAYLIGHT: Negative
- Mechanism: BACE inhibitor
- Phase III: Stopped for cognitive worsening
- MISSION AD: Negative
- Mechanism: Anti-tau antibody targeting N-terminus
- Phase II: Negative in PSP (LIGUSTRING)
- TAURIELD: Ongoing in AD
- Mechanism: Anti-tau antibody
- Phase II: Negative in prodromal/mild AD (LAURIET)
- Phase II: Negative in moderate AD (AMBITION)
- Mechanism: Anti-tau N-terminal antibody
- Phase II: Negative in AD (TANGO)
- Mechanism: Anti-tau antibody
- Phase II: Ongoing in AD
- Mechanism: Tau aggregation inhibitor
- Phase III: Negative in mild AD (ROCKET)
- Formulation issues: Bioavailability
- Mechanism: Microtubule stabilizer
- Phase III: Negative in PSP (ALLATOR)
- Mechanism: Tyrosine kinase inhibitor
- Phase III: Positive signal in mild-to-moderate AD
- AB10015: 60% slowing in cognitive decline
- Mechanism: Myeloid stimulation
- Phase II: Positive signal in AD
- Immunity and AD study
- Mechanism: SV2A modulator
- Phase II: Reduced hippocampal hyperactivity
- 、改善了轻度认知障碍患者的记忆力
- Mechanism: Negative allosteric modulator of muscarinic M1
- Phase II: Negative in mild AD
- Amyloid removal + tau targeting
- Amyloid + neuroinflammation
- Multi-target therapies
- Synaptic plasticity and function
- Mitochondrial dysfunction
- Neurovascular unit
- Microbiome-gut-brain axis
- Biomarker confirmation (amyloid PET, CSF)
- Disease stage
- Comorbidities
- APOE status
- ARIA surveillance (for monoclonal antibodies)
- Cognitive assessments
- Functional measures
- Biomarker changes
The study of Disease Modifying Therapies For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] van Dyck CH, et al. N Engl J Med. 2023;388(1):9-21. PMID:36459553
[2] Sims JR, et al. JAMA. 2023;329(13):1083-1097. PMID:36961827
[3] Swaddiwudhipong N, et al. Nat Rev Neurol. 2023;19(12):715-728. PMID:37993563
[4] Liu KY, et al. Nat Rev Drug Discov. 2023;22(10):779-799. PMID:37758986
[5] Mintun MA, et al. N Engl J Med. 2021;384(18):1691-1704. PMID:33951237
[6] Herring WL, et al. J Prev Alzheimers Dis. 2024;11(1):9-18. PMID:38218724
[7] Karran E, et al. Nat Rev Drug Discov. 2024;23(2):87-108. PMID:38129473
[8] Hampel H, et al. Mol Psychiatry. 2024;29(2):427-445. PMID:38148394